<DOC>
	<DOCNO>NCT01532635</DOCNO>
	<brief_summary>This phase II clinical trial study well two donor stem cell transplant work treat patient high-risk hematologic malignancy . After receive radiation help treat disease , patient receive dose donor ' T cell . T cell fight infection react cancer cell . Two day donor ' T cell give , patient receive cyclophosphamide ( CY ) help destroy active T cell may cause tissue damage ( call graft versus host disease GVHD ) . Some less reactive T cell destroy CY remain patient help fight infection . A day CY give , patient receive donor ' stem cell help blood count recover . Using two donor ' stem cell transplant instead one donor may effective treat patient high-risk disease may prevent disease come back .</brief_summary>
	<brief_title>A Two-Step Approach Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess 1 year relapse free survival patient undergoing hematopoietic stem cell transplant ( HSCT ) use Thomas Jefferson University ( TJU ) 2 step approach use 2 donor . SECONDARY OBJECTIVES : I . To assess consistency pace engraftment . II . To assess pace T cell B cell immune recovery patient arm . III . To assess regimen related toxicity , graft-versus-host disease ( GVHD ) incidence severity , overall survival . IV . To assess tolerance period fever , diarrhea , rash introduction second donor qualitatively compare prior patient group concurrent patient group . V. To assess chimerism ascertain whether one donor emerge dominant regular interval begin time engraftment . VI . If dominance observe , compare donor regard degree human leukocyte antigen ( HLA ) mismatch , killer Ig-like receptor ( KIR ) type , cluster differentiation ( CD ) 34+ cell dos , infusion order , donor age , donor alloreactivity point effort identify potential biologic factor predict dominance . To determine trend toward dominance occur T cell , natural killer ( NK ) cell , cellular subset prior emerge graft whole . VII . To assess establishment dominant donor versus persistent chimerism donor associate low relapse rate . VIII . To collect leukemia sample prior transplant relapse whenever possible . To assess overall degree HLA-class I class II expression pair sample . To test loss one HLA haplotype relapse tumor specimen . When observed , correlate loss one HLA haplotype : ) receipt transplant capable target haplotype ; b ) establishment dominance 2 haplotype transplant lose haplotype would primary target dominant donor ; c ) target donor predict alloreactive 2 haplotype transplant . OUTLINE : CONDITIONING : Patients undergo total-body irradiation ( TBI ) twice daily ( BID ) day -9 -6 , undergo donor lymphocyte infusion ( DLI ) day -6 , receive cyclophosphamide intravenously ( IV ) 2 hour day -3 -2 . TRANSPLANTATION : Patients undergo CD34+ select allogeneic HSCT day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV orally ( PO ) begin day -1 taper begin day 42 mycophenolate mofetil IV PO BID day -1 28 . After completion study treatment , patient follow 1 year , periodically thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Any patient hematologic malignancy residual disease ( morphological , cytogenetic , molecular , radiographic ) treatment 1 chemotherapy regimen achievement remission additional chemoradiotherapy felt unlikely 3rd great CR . Patients marrow base disease marrow biopsy meet criterion active disease ( i.e . &lt; 5 % blast acute leukemia ) full count recovery eligible treatment high risk trial . 2 . Patients must two related donor meet acceptable scenario describe . 3 . Patients must adequate organ function : LVEF &gt; = 50 % DLCO ( adjust hemoglobin ) &gt; = 50 % predicted Adequate liver function define serum bilirubin = &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal Creatinine clearance &gt; = 60 ml/min 4 . Karnofsky Performance Status &gt; 80 % modify KPS tool ( see Appendix A ) . 5 . Patients must willing use contraception childbearing potential . 6 . Able give inform consent 1 . Modified KPS &lt; 80 % 2 . &gt; = 5 Comorbidity Points HCTCI Index ( See Appendix B ) 3 . Class I II antibody donor HLA antigens 4 . HIV positive 5 . Active involvement central nervous system malignancy 6 . Psychiatric disorder would preclude patient sign informed consent 7 . Pregnancy , unwillingness use contraception child bear potential 8 . Patients life expectancy = &lt; 6 month reason underlie hematologic/oncologic disorder 9 . Alemtuzumab treatment within 8 week HSCT admission . 10 . ATG level &gt; = 2 ugm/ml 11 . Patients active inflammatory process ( flair autoimmune disease ) include T max &gt; 101 , active tissue inflammation exclude . 12 . Inability tolerate cyclophosphamide undergo total body irradiation dose specify treatment plan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hematologic malignancy</keyword>
	<keyword>leukemia</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>lymphoma</keyword>
	<keyword>hodgkin 's lymphoma</keyword>
	<keyword>non-hodgkin 's lymphoma</keyword>
	<keyword>myeloma</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>TJU 2-step</keyword>
	<keyword>Hematopoietic stem cell transplant</keyword>
	<keyword>HSCT</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>MMF</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
</DOC>